Reducing the Risk of Adverse Events in Patients with Type 2 Diabetes Who are Poorly Treated with Metformin Combined with Acarbose：Dipeptidyl Peptidase-4 Inhibitor is Better Than Insulin

Reducing the Risk of Adverse Events in Patients with Type 2 Diabetes Who are Poorly Treated with Metformin Combined with Acarbose：Dipeptidyl Peptidase-4 Inhibitor is Better Than Insulin

BackgroundClinically, when metformin (Met) combined with acarbose (Aca) cannot achieve the ideal hypoglycemic effect, a third drug will be usually added, such as insulin (Ins) or dipeptidyl peptidase-4 inhibitor (DPP-4i) etc., but there are few reports on the effect of triple therapy on complication...

Cijeli opis

Bibliografski detalji
Glavni autor: SU Peng, LIU Yukun, LIANG Xiaohua, LIU Xin, YU Yaohui, HUANG Pengfei, BAI Yuru, HE Xiaoyan, SHEN Zhihong, MA Dong
Format: Članak
Jezik:zho
Izdano: Chinese General Practice Publishing House Co., Ltd 2022-03-01
Serija:Zhongguo quanke yixue
Teme:
|diabetes mellitus, type 2|dipeptidyl-peptidaseⅳ inhibitors|metformin|acarbose|drug-related side effects and adverse reactions|cohort studies|retrospective studies
Online pristup:https://www.chinagp.net/fileup/1007-9572/PDF/yx202202022.pdf

Internet

https://www.chinagp.net/fileup/1007-9572/PDF/yx202202022.pdf

Slični predmeti